Search
Piroxicam
go.drugbank.com/drugs/DB00554ApprovedInvestigationalA cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea
Synonyms: 4-Hydroxy-2-methyl-N-(2-pyridyl)-2H-1,2-benzothiazin-3-caboxyamid-1,1-dioxidProducts: PIROXICAM EG, ILMODOL DOLORE E INFIAMMAZIONEBretylium
go.drugbank.com/drugs/DB01158ApprovedBretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular
Synonyms: 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium, N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminiumTriethylenetetramine
go.drugbank.com/drugs/DB06824ApprovedInvestigational[A19333] Initially approved by the FDA in 1985 as a second-line treatment for Wilson's disease,[A19334] TETA is currently indicated to treat adults with stable Wilson’s disease who are de-coppered and … TETA was first developed in Germany in 1861 and its chelating properties were first recognized in 1925.
Categories: Compounds used in a research, industrial, or household settingGabapentin
go.drugbank.com/drugs/DB00996ApprovedInvestigationalGabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. … stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in
Mixtures: GAVINDO NProducts: GABAPENTIN EGEtoricoxib
go.drugbank.com/drugs/DB01628ApprovedInvestigationalWithdrawnIt is approved in more than 60 countries worldwide but not in the US.
Products: ETORICOXIB EGRelatlimab
go.drugbank.com/drugs/DB14851ApprovedInvestigational[L41300] Opdualag was subsequently approved in the European Union in July 2022[L49996] and in Canada in September 2023.[L50001] … [A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and has garnered interest in the treatment of a variety of cancers, including leukemia
Ropeginterferon alfa-2b
go.drugbank.com/drugs/DB15119ApprovedInvestigational[A242015, L39170] Ropeginterferon alfa-2b has shown efficacy in PV in _in vitro_ and _in vivo_ models and clinical trials. … Polycythemia vera (PV) is the most common Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), characterized by increased hematocrit and platelet/leukocyte counts, an increased risk for
Products: BESREMi PenEtoposide
go.drugbank.com/drugs/DB00773ApprovedInvestigationalAccumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. … This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding.
Products: INJECTION ETOPOSIDE CS 100MG IN 5MLNafcillin
go.drugbank.com/drugs/DB00607ApprovedInvestigationalIt may be used as a first-line therapy in Methicillin-Sensitive *Staphylococcus aureus* infections [A20360].
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnwith first-line therapies, putting them in a risk for poor outcomes and creating a significant clinical challenge [A31818]. … Based on its tolerability and safety profile, remestemcel-L is a promising alternative to second-line immunosuppressive agents [A31818].